Comparative Pharmacology
Head-to-head clinical analysis: SODIUM IODIDE I 123 versus VIZAMYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SODIUM IODIDE I 123 versus VIZAMYL.
SODIUM IODIDE I 123 vs VIZAMYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sodium iodide I 123 is a radioactive isotope that emits gamma radiation. Following oral or intravenous administration, it is rapidly absorbed and selectively concentrated in the thyroid gland via the sodium-iodide symporter (NIS). The emitted gamma rays allow for imaging of thyroid tissue and detection of abnormal uptake patterns.
Vizamyl is a radiopharmaceutical that binds to beta-amyloid plaques in the brain, enabling visualization via PET imaging.
Oral: 400-800 μCi (14.8-29.6 MBq) for thyroid uptake studies; 150-300 μCi (5.6-11.1 MBq) for thyroid scan. Administer orally as a single dose.
For diagnostic imaging: 370 MBq (10 mCi) administered as a slow intravenous bolus (approximately 1 mL/sec).
None Documented
None Documented
13.2 hours (physical T1/2); effective T1/2 ~13 hours in euthyroid; prolonged in hypothyroidism.
Terminal elimination half-life is approximately 45-50 minutes in patients with normal renal function, allowing for rapid clearance and early imaging within 4 hours post-injection.
Primarily renal (90%) as iodide; small amount feces (<5%) and negligible biliary.
Primarily renal excretion as unchanged drug (90-95%) with the remainder excreted via feces (5-10%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical